Roche CERA submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche's long-acting anemia agent CERA has an estimated mid-February 2007 user fee date following the firm's recent submission of a BLA, announced April 20. The firm is seeking an indication for anemia associated with chronic kidney disease. Roche highlighted the continuous erythropoietin receptor activator as having a distinct molecular interaction from that of other erythropoietin agents. The BLA is supported by six Phase III trials of patients treated every four weeks. Roche is continuing to point to CERA's dosing advantages. The firm also plans to submit a chemotherapy-induced anemia BLA in 2009 (1Pharmaceutical Approvals Monthly February 2006, p. 15)...
You may also be interested in...
Roche Delays CERA Oncology Filing Until 2009
Roche is pushing back the timeline for filing its anti-anemia agent CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the firm said Feb. 1
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
FDA Sets New Restrictions For Authorized N95 Decontamination Systems
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: